Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Context Therapeutics Inc. - Common Stock
(NQ:
CNTX
)
1.260
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
11,305
Open
1.260
Bid (Size)
1.260 (13)
Ask (Size)
1.350 (22)
Prev. Close
1.260
Today's Range
1.260 - 1.260
52wk Range
0.4900 - 2.590
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
October 06, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Performance
YTD
+5.9%
+5.9%
1 Month
+48.6%
+48.6%
3 Month
+38.2%
+38.2%
6 Month
+49.4%
+49.4%
1 Year
-38.5%
-38.5%
More News
Read More
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
October 02, 2025
Via
Benzinga
Context Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) Posts Wider Q2 2025 Loss Amid Continued Pipeline Progress
August 06, 2025
Via
Chartmill
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
August 06, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 05, 2025
Via
Benzinga
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
June 02, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
May 29, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
May 07, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Chief Medical Officer Transition
May 05, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
April 30, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
April 09, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Unusual volume stocks in Friday's session
April 04, 2025
Via
Chartmill
These stocks that are showing activity before the opening bell on Thursday.
April 03, 2025
Via
Chartmill
Context Therapeutics to Participate in Upcoming Investor Conferences
April 01, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
March 26, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-03-25: top gainers and losers in today's session.
March 25, 2025
Via
Chartmill
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
March 20, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 17, 2025
Via
Benzinga
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 24, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Context Therapeutics to Participate in Upcoming Investor Conferences
February 19, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 15, 2025
Via
Benzinga
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
January 14, 2025
From
Context Therapeutics Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Context Therapeutics Inc. - Common Stock publicly traded?
Yes, Context Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Context Therapeutics Inc. - Common Stock trade on?
Context Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Context Therapeutics Inc. - Common Stock?
The ticker symbol for Context Therapeutics Inc. - Common Stock is CNTX on the Nasdaq Stock Market
What is the current price of Context Therapeutics Inc. - Common Stock?
The current price of Context Therapeutics Inc. - Common Stock is 1.260
When was Context Therapeutics Inc. - Common Stock last traded?
The last trade of Context Therapeutics Inc. - Common Stock was at 10/16/25 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.